Applications of new drug delivery technologies to Parkinson’s disease and dopaminergic agents

  • S. M. Stahl
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)


Recent advances in drug delivery technology are creating novel therapeutic approaches to the treatment of Parkinson’s disease with levodopa and dopamine agonists. This article reviews those technologies which can be applied to Parkinson’s disease, both for targetting the central nervous system with drugs, as well as for matching the appropriate rate controlled delivery with therapeutic needs. In particular, the possibility exists for eliminating erratic highs and lows of drug delivery to the brain, and to substitute rate controlled, constant drug delivery. Clinical investigations now in progress suggest that new technologies which deliver constant dopaminergic stimulation to patients with Parkinson’s disease may not only eliminate the unpredictable swings in therapeutic efficacy in Parkinson patients with the “on/off” effect, but may even have a role in the future in preventing such fluctuations from developing in patients chronically treated with dopaminergic therapies.


Drug Delivery Motion Sickness Growth Hormone Receptor Drug Delivery Device Ommaya Reservoir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bates IP (1984) The blood brain barrier and central nervous system penetration. Pharm J 30: 265–268Google Scholar
  2. Bodor N, Simpkins JW (1983) Redox delivery system for brain-specific sustained release of dopamine. Science 221: 65–67PubMedCrossRefGoogle Scholar
  3. Costall B, Domeney AM, Naylor RJ (1983) A comparison of the behavioural consequences of chronic stimulation of dopamine receptors in the nucleus accumbens of rat brain effected by a continuous infusion or by single daily injections. Naunyn Schmiedebergs Arch Pharmacol 324: 27–33PubMedCrossRefGoogle Scholar
  4. Costall B, Domeney AM, Naylor RJ (1984) Locomotor hyperactivity caused by dopamine infusion into the nucleus accumbens of rat brain: specificity of action. Psychopharmacology 82: 174–180PubMedCrossRefGoogle Scholar
  5. Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R (1981) Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 65: 393–400PubMedGoogle Scholar
  6. Gardner CR (1985) Chemical approaches to drug delivery to the central nervous system. Psychopharmacol Bull 21: 657–662PubMedGoogle Scholar
  7. Goldman P (1982) Rate-controlled drug delivery. N Eng J Med 307: 286–290CrossRefGoogle Scholar
  8. Harbaugh RE, Roberts DW, Coombs DW, Saunders RL, Reeder TM (1984) Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer’s disease. Neurosurgery 15: 514–518PubMedCrossRefGoogle Scholar
  9. Henderson NL (1983) Recent advances in drug delivery systems technology. In: Allen RC (ed) Annual reports in medicinal chemistry. Academic Press, New York, pp 275–284Google Scholar
  10. Kokkinidis L (1984) Effects of chronic intermittent and continuous amphetamine administration on acoustic startle. Pharmacol Biochem Behav 20: 367–371PubMedCrossRefGoogle Scholar
  11. Martin-Iverson M, Stahl SM, Iversen SD (1987) Factors determining the behavioural consequences of continuous treatment with 4-propyl-9-hydroxynaphthoxazine, a selective dopamine D2 agonist. In: Rose FC (ed) Parkinson’s disease. J Libbey, London pp 169–177Google Scholar
  12. Mecklenburg RS, Benson EA, Benson JW, Blumenstein BA, Fredlund PM, Guinn TS, Metz RJ, Nielsen RL (1985) Longterm metabolic control with insulin pump therapy. N Eng J Med 313: 465–468CrossRefGoogle Scholar
  13. Norstedt G, Palmiter R (1984) Secretory rhythm of growth hormone regulate sexual differentiation of mouse liver. Cell 36: 805–812PubMedCrossRefGoogle Scholar
  14. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The “on-off” phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N Engl J Med 310: 483–488PubMedCrossRefGoogle Scholar
  15. Obeso JA, Luquin MR, Martinez-Lage JM (1986 a) Lisuride infusion pump: a device for the treatment of motor fluctuation in Parkinson’s disease. Lancet 1: 467–470Google Scholar
  16. Obeso JA, Luquin MR, Martinez-Lage JM (1986 b) Intravenous lisuride corrects oscillations of motor performance in Parkinson’s disease. Ann Neurol 19: 31–35Google Scholar
  17. Ommaya AK (1984) Implantable devices for chronic access and drug delivery to the central nervous system. Cancer Drug Deliv 1: 169–179PubMedCrossRefGoogle Scholar
  18. Quinn N, Marsden CD, Parkes JD (1982) Complicated response to intravenous infusion of levodopa. Lancet 2: 412–415PubMedCrossRefGoogle Scholar
  19. Salzman R, Manson JE, Griffing GT, Kimmerle R, Ruderman N, McCall A, Stoltz EI, Mullin C, Small D, Armstrong J, Melby JC (1985) Intranasal aerosolized insulin: mixed- meal studies and long term use in Type I diabetes. N Engl J Med 312: 1078–1084PubMedCrossRefGoogle Scholar
  20. Shaw JE, Chandrasekaran SK (1978) Controlled topical delivery of drugs for systemic action. Drug Metab Rev 8: 223–233PubMedCrossRefGoogle Scholar
  21. Stahl SM (1985) New drug delivery systems-a new approach to Parkinson’s disease. In: Marsden CD, Trimble M (eds) Future trends in the treatment of Parkinson’s disease and epilepsy. Franklin Scientific Projects Publications, London, pp 16–18Google Scholar
  22. Urquhart J, Fara JW, Willis KL (1984) Rate-controlled delivery systems in drug and hormone research. Ann Rev Pharmacol Toxicol 24: 199–236CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • S. M. Stahl
    • 1
    • 2
  1. 1.Merck Sharp & Dohme Research LaboratoriesNeuroscience Research CentreHarlow, EssexUK
  2. 2.Institute of PsychiatryUniversity of LondonLondonUK

Personalised recommendations